Abrégé

The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
• A61K 38/37 - Facteurs VIII
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
• A61K 31/02 - Hydrocarbures halogénés
• A61K 31/025 - Hydrocarbures halogénés carbocycliques
• A61K 31/035 - Hydrocarbures halogénés ayant une insaturation aliphatique
• A61K 33/16 - Composés du fluor
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique

Abrégé

The present disclosure relates to a composition for increasing the expression of a growth factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with a growth factor gene, the composition for increasing the expression of a growth factor gene of the present disclosure can increase the expression of the co-administered gene by at least 30%. Especially, when administered along with at least one gene selected from a human hepatocyte growth factor (HGF) gene, an isoform gene of the human hepatocyte growth factor and a variant gene thereof, or at least one gene selected from a human insulin-like growth factor 1 (IGF1) gene, an isoform gene of the human insulin-like growth factor 1 and a variant gene thereof, which are appropriate for the present disclosure, the composition can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61K 31/02 - Hydrocarbures halogénés
• A61K 31/025 - Hydrocarbures halogénés carbocycliques
• A61K 31/035 - Hydrocarbures halogénés ayant une insaturation aliphatique
• A61K 33/16 - Composés du fluor
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• A61K 38/37 - Facteurs VIII
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques

Produits et services

Medicine cases, portable, filled; pharmaceutical agents affecting metabolism; vitamin and mineral preparations; crude medicines; anti-inflammatory and antipyretic preparations; cardiovascular pharmaceutical preparations; dietetic food supplements; food for babies; preparations of microorganisms for medical or veterinary use; medical and surgical plasters; diagnostic reagents and contrast media for medical purposes; hormones for medical purposes; pharmaceuticals; pharmaceutical and veterinary preparations; pharmaceutical preparations; nutraceutical preparations for therapeutic or medical purposes; antibiotics; anti-cancer preparations; pharmaceutical preparations for respiratory organs. Retail store services featuring vitamin and mineral dietary supplements; sales agency services for health food supplements made principally of vitamins; wholesale store services featuring dietary supplements; retail store services featuring dietary supplements; retail store services featuring dietary supplements consisting of amino acids, minerals and trace elements; wholesale store services featuring drugs for medical purposes; retail store services featuring drugs for medical purposes; sales arranging of pharmaceuticals; sales agency services for pharmaceuticals; wholesale store services featuring medicines for human purposes; retail store services featuring medicines for human purposes; sales agency services for medicines for human purposes; sales arranging of medicines for human purposes; promoting the goods and services of others by means of operating an on-line comprehensive shopping mall; business intermediary services relating to mail order by telecommunications; wholesale store services featuring analgesics; retail store services featuring nutraceuticals for therapeutic purposes; sales agency services for nutraceutical preparations for therapeutic or medical purposes.

Produits et services

Medicine cases, portable, filled; pharmaceutical agents affecting metabolism; vitamin and mineral preparations; crude medicines; anti-inflammatory and antipyretic preparations; cardiovascular pharmaceutical preparations; dietetic food supplements; food for babies; preparations of microorganisms for medical or veterinary use; medical and surgical plasters; diagnostic reagents and contrast media for medical purposes; hormones for medical purposes; pharmaceuticals; pharmaceutical and veterinary preparations; pharmaceutical preparations; nutraceutical preparations for therapeutic or medical purposes; antibiotics; anti-cancer preparations; pharmaceutical preparations for respiratory organs. Retail store services featuring vitamin and mineral dietary supplements; sales agency services for health food supplements made principally of vitamins; wholesale store services featuring dietary supplements; retail store services featuring dietary supplements; retail store services featuring dietary supplements consisting of amino acids, minerals and trace elements; wholesale store services featuring drugs for medical purposes; retail store services featuring drugs for medical purposes; sales arranging of pharmaceuticals; sales agency services for pharmaceuticals; wholesale store services featuring medicines for human purposes; retail store services featuring medicines for human purposes; sales agency services for medicines for human purposes; sales arranging of medicines for human purposes; promoting the goods and services of others by means of operating an on-line comprehensive shopping mall; business intermediary services relating to mail order by telecommunications; wholesale store services featuring analgesics; retail store services featuring nutraceuticals for therapeutic purposes; sales agency services for nutraceutical preparations for therapeutic or medical purposes.

Produits et services

Medicine cases, portable, filled; pharmaceutical agents affecting metabolism; vitamin and mineral preparations; crude medicines; anti-inflammatory and antipyretic preparations; cardiovascular pharmaceutical preparations; dietetic food supplements; food for babies; preparations of microorganisms for medical or veterinary use; medical and surgical plasters; diagnostic reagents and contrast media for medical purposes; hormones for medical purposes; pharmaceuticals; pharmaceutical and veterinary preparations; pharmaceutical preparations; nutraceutical preparations for therapeutic or medical purposes; antibiotics; anti-cancer preparations; pharmaceutical preparations for respiratory organs.

Abrégé

The present invention relates to a composition for alleviating, treating, or preventing allergic or inflammatory skin diseases and, more specifically, contains, as an active ingredient, a Thymus vulgaris extract, or a Thymus vulgaris extract and an Echinacea purpurea juice so as to reduce an ear edema in an inflammatory skin disease animal model, reduce the levels of total leukocytes, neutrophils, eosinophils, and blood IgE and the like in blood tests, and reduce, histopathologically, the levels of inflammatory cell infiltration and mast cell infiltration in the epidermis, and thus can be usable as a pharmaceutical composition for treating or preventing allergic or inflammatory skin diseases, a pharmaceutical composition for treating or preventing allergic or inflammatory skin diseases in animals, a food composition for alleviating allergic or inflammatory skin diseases, or a feed composition for alleviating allergic or inflammatory skin diseases.

Classes IPC  ?

• A61K 36/53 - Lamiaceae ou Labiatae (famille de la menthe), p. ex. thym, romarin ou lavande
• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 37/08 - Agents antiallergiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons

Abrégé

The present invention relates to a composition for ameliorating, treating, or preventing allergic or inflammatory skin diseases. More specifically, the composition comprises Echinacea purpurea juice as an active ingredient, and thus relieves edema of the ears of an inflammatory skin disease animal model and reduces the levels of whole white blood cells, neutrophils, eosinophils, blood IgE, and the like in a blood test, and accordingly, can be used as a pharmaceutical composition for treating or preventing allergic or inflammatory skin diseases, a pharmaceutical composition for use in animals for treating or preventing allergic or inflammatory skin diseases, a food composition for ameliorating allergic or inflammatory skin diseases, or a feed composition for ameliorating allergic or inflammatory skin diseases.

Classes IPC  ?

• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 37/08 - Agents antiallergiques
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to an oral composition for reducing body weight or body fat. More specifically, the present invention contains Artemisia dracunculus and Taraxacum officinale as active ingredients so as to enable a reduction in body weight or body fat and also a reduction in blood ALT, blood triglycerides and blood cholesterol, thereby being usable as a food composition for reducing body weight or body fat, and also as a health functional food for reducing body weight or body fat, a feed composition for reducing body weight or body fat, an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disorders, or an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disorders in animals.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/282 - Artemisia, p. ex. armoise
• A61K 36/288 - Taraxacum (pissenlit)
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A23P 10/28 - Mise en comprimésFabrication de produits alimentaires en barres par compression d’un mélange pulvérulent sec
• A23L 2/04 - Extraction des jus
• A61P 3/04 - AnorexigènesMédicaments de l'obésité

Produits et services

Pharmaceutical agents affecting metabolism; vitamin and mineral preparations for medical use; crude medicines, namely, medicines for the treatment and prevention of atopic skin disease, obesity, digestive disorders, and immune system related diseases and disorders; anti-inflammatory and antipyretic preparations; cardiovascular pharmaceutical preparations; dietetic food supplements; food for babies; preparations of microorganisms for medical or veterinary use; medical and surgical plasters; pharmaceutical and veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, and immune system related diseases and disorders; pharmaceutical and veterinary preparations for treating allergic rhinitis and asthma; pharmaceutical and veterinary preparations for ocular and intraocular surgery; pharmaceutical and veterinary preparations acting on the central nervous system; pharmaceutical and veterinary preparations for the prevention of osteoporosis; pharmaceutical and veterinary preparations for use in urology; pharmaceutical and veterinary preparations, namely, drug delivery systems comprising polymer-based oral tablets for the continuous release of therapeutic agents; pharmaceutical and veterinary preparations for use in the anesthesia; pharmaceutical and veterinary preparations for diagnostic purposes; pharmaceutical and veterinary preparations for the peripheral nervous system; pharmaceutical and veterinary preparations for digestive organs; pharmaceutical and veterinary preparations for anti-fungal treatment; nutraceutical preparations for therapeutic or medical purposes; antibiotics; anti-cancer preparations; pharmaceutical preparations for respiratory organs; all aforementioned goods sold only to hospitals or other healthcare institutions and to pharmaceutical companies Wholesale store services featuring dietary supplements for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; wholesale store services featuring drugs for medical purposes for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; wholesale store services featuring medicines for human purposes for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; business intermediary services relating to mail order by telecommunications, namely, mail order pharmacy services for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; wholesale store services featuring analgesics for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies

Produits et services

Pharmaceutical agents affecting metabolism; vitamin and mineral preparations for medical use; crude medicines, namely, medicines for the treatment and prevention of atopic skin disease, obesity, digestive disorders, and immune system related diseases and disorders; anti-inflammatory and antipyretic preparations; cardiovascular pharmaceutical preparations; dietetic food supplements; food for babies; preparations of microorganisms for medical or veterinary use; medical and surgical plasters; pharmaceutical and veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, and immune system related diseases and disorders; pharmaceutical and veterinary preparations for treating allergic rhinitis and asthma; pharmaceutical and veterinary preparations for ocular and intraocular surgery; pharmaceutical and veterinary preparations acting on the central nervous system; pharmaceutical and veterinary preparations for the prevention of osteoporosis; pharmaceutical and veterinary preparations for use in urology; pharmaceutical and veterinary preparations, namely, drug delivery systems comprising polymer-based oral tablets for the continuous release of therapeutic agents; pharmaceutical and veterinary preparations for use in the anesthesia; pharmaceutical and veterinary preparations for diagnostic purposes; pharmaceutical and veterinary preparations for the peripheral nervous system; pharmaceutical and veterinary preparations for digestive organs; pharmaceutical and veterinary preparations for anti-fungal treatment; nutraceutical preparations for therapeutic or medical purposes; antibiotics; anti-cancer preparations; pharmaceutical preparations for respiratory organs; all aforementioned goods sold only to hospitals or other healthcare institutions and to pharmaceutical companies

Produits et services

Pharmaceutical agents affecting metabolism; vitamin and mineral preparations for medical use; crude medicines, namely, medicines for the treatment and prevention of atopic skin disease, obesity, digestive disorders, and immune system related diseases and disorders; anti-inflammatory and antipyretic preparations; cardiovascular pharmaceutical preparations; dietetic food supplements; food for babies; preparations of microorganisms for medical or veterinary use; medical and surgical plasters; pharmaceutical and veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, and immune system related diseases and disorders; pharmaceutical and veterinary preparations for treating allergic rhinitis and asthma; pharmaceutical and veterinary preparations for ocular and intraocular surgery; pharmaceutical and veterinary preparations acting on the central nervous system; pharmaceutical and veterinary preparations for the prevention of osteoporosis; pharmaceutical and veterinary preparations for use in urology; pharmaceutical and veterinary preparations, namely, drug delivery systems comprising polymer-based oral tablets for the continuous release of therapeutic agents; pharmaceutical and veterinary preparations for use in the anesthesia; pharmaceutical and veterinary preparations for diagnostic purposes; pharmaceutical and veterinary preparations for the peripheral nervous system; pharmaceutical and veterinary preparations for digestive organs; pharmaceutical and veterinary preparations for anti-fungal treatment; nutraceutical preparations for therapeutic or medical purposes; antibiotics; anti-cancer preparations; pharmaceutical preparations for respiratory organs; all aforementioned goods sold only to hospitals or other healthcare institutions and to pharmaceutical companies Wholesale store services featuring dietary supplements for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; wholesale store services featuring drugs for medical purposes for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; wholesale store services featuring medicines for human purposes for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; business intermediary services relating to mail order by telecommunications, namely, mail order pharmacy services for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies; wholesale store services featuring analgesics for goods and services sold only to hospitals or other healthcare institutions and to pharmaceutical companies

Abrégé

in vivoin vivo along with a gene, the composition for increasing the expression of a growth factor gene, according to the present invention, may increase the expression of the co-administered gene by at least 30% or higher. Especially, when administered along with at least one type of gene, appropriate for the present invention, selected from a human hepatocyte growth factor (HGF) gene, a variant gene of the human HGF and a mutant gene thereof, or at least one type of gene, appropriate for the present invention, selected from a human insulin-like growth factor-1 (IGF-1) gene, a variant gene of the human IGF-1 and a mutant gene thereof, the composition may increase the expression of the gene by at least 30% or higher. When administered along with a gene therapeutic agent, the composition may enable a treatment effect to be achieved even by means of a small amount of a gene, and thus the composition is useful.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques

Abrégé

in vivoin vivo along with the blood coagulation factor VIII or a mutant gene thereof, the composition for increasing the expression of a blood coagulation factor gene, according to the present invention, may increase the expression of the gene by at least 30% or higher. When administered along with a gene therapeutic agent, the composition may enable a treatment effect to be achieved even by means of a small amount of a gene, and thus the composition is useful.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques

Abrégé

The present invention relates to an expression vector that carries a polynucleotide coding for a coagulation factor VIII variant and increases protein expression capacity, and a pharmaceutical composition comprising the expression vector for preventing or treating hemorrhagic disease or hemorrhage. The factor VIII variant of the present invention is derived by deleting a part (residues 784-1667) of the B-domain and a part (residues 1668-1671) of the a3 region in factor VIII and, as a result, an expression vector carrying a polynucleotide coding for the factor VIII variant is remarkably increased in protein expression capacity.

Classes IPC  ?

• C12N 15/67 - Méthodes générales pour favoriser l'expression
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 9/10 - Transférases (2.)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/00 - Préparations médicinales contenant des peptides

Produits et services

Pharmaceuticals; therapeutic drugs and agents; non-prescription medicines; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical agents affecting digestive organs; pharmaceutical products for treating respiratory diseases; pharmaceutical preparations for use in urology; ocular pharmaceuticals; antibiotics; anti-inflammatory preparations; pharmaceutical preparations for the treatment of osteoporosis; antihistamines; psychotropics; tumor suppressing agents; anti-cancer preparations; anaesthetics; autonomic drugs for medical purposes; hormone preparations for pharmaceutical use; contrast media for medical purposes; antivirals; diagnostic preparations for medical purposes; chemico-pharmaceutical preparations.

Abrégé

Candida, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.

Classes IPC  ?

• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine